Evernorth, the health services arm of Cigna Corporation (NYSE:CI), added five new application-based programs to its Digital Health Formulary to help people get help with anxiety, alcohol, opioid use disorders, inflammatory conditions and sleep issues.
The proposed solutions have been subject to review by physicians, pharmacists, and user experience experts with each solution subject to standards for clinical effectiveness, privacy requirements, value, usability and compliance security.
“Evernorth continues to expand our Digital Health Formulary to address unmet health care needs of patients with chronic and complex medical conditions. The latest additions give patients access to new and affordable options to improve and maintain their health while making it easier and cost effective for our clients to include these solutions in their benefit plans. The Digital Health Formulary is one of the ways we can connect employers, insurers, and patients with innovative, affordable, and evidence-based care that meet their broader health care needs,” said Dr. Glen Stettin, chief innovation officer, Evernorth.
What is Evernorth?
The above is an example of one of Evernorth’s core competencies. It makes and connects premier health service offerings, including care solutions, sights and intelligence, as well as benefits management and pharmacy. The company produces solutions for health plans, employers and government programs. Evernorth’s capabilities are fuelled by a family of companies, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore and MDLIVE.
The company added five digital solutions to the digital health formulary. These include a single Big Health Sleepio for both insomnia and anxiety, two Quit Genius programs for alcohol use disorder and opioid use disorder, which round up a suite of addiction support solutions from Quit Genius, and HealthBeacon’s Injectable Care Management System for inflammatory conditions.
Benefit plans extended to over 20 million members in the United States offer potential solutions from the formulary to their members, and in turn, deliver administrative savings of up to $120,000 per solution.
Plan sponsors can choose between individual digital solutions or bundle them together into a connected care program, using biometric data from the digital health solutions with pharmacy, medical and lab data, while protecting the patient’s privacy. Here plan sponsors can recognize and fill holes in care and health opportunities than if it were using a standalone solution, which means better outcomes for patients, improved insight for providers and greater value overall.
Beyond insomnia and addiction, though, Evernorth has a series of pilot programs for the formulary intended to determine the clinical impact and user experience for solutions dealing with oncology, psoriasis and eczema, women’s pelvic health and ensuring medication treatment adherence.